2016-08-11T15:00:34-07:00 2015-12-31 990 2015-01-01 236434390 THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY WIST 2158989910 3601 Spruce Street Philadelphia PA 191044265 Joseph G Trainor Chief Financial Officer 2154956922 2016-08-12 2015 2016-12-15 16:53:06Z Joseph G Trainor 3601 Spruce Street Philadelphia PA 19104 135754576 0 X www.wistar.org X 1892 PA Biomedical research with special expertise in cancer research and vaccine development. 33 33 382 51 108000 -129000 39654000 45984000 3108000 3295000 7964000 1248000 18232000 41710000 68958000 92237000 0 0 0 0 27573000 26233000 0 0 628000 30335000 32923000 57908000 59156000 11050000 33081000 241477000 267442000 80752000 73735000 160725000 193707000 X The mission of the Wistar Institute is to marshal the talents of outstanding scientists through a highly enabled culture of biomedical collaboration and innovation in order to solve some of the world's most challenging and important problems in the field of cancer and immunology, and produce ground-breaking advances in world health. Consistent with a pioneering legacy of leadership in not-for-profit biomedical research and a track-record of life-saving contributions in immunology and cell biology, The Wistar Institute aims to pursue novel and courageous research paths to life science discovery, and to accelerate/potentiate the impact of those discoveries by shortening the path from bench to bedside. 0 0 46505000 3295000 Wistar recognizes that collaboration is one of its traditional strengths, which is why the Institute takes a team science approach to translating basic scientific discoveries into practical therapies. Researchers at the Institute operate within the framework of one of the Cancer Center's program cores, and they benefit from the Shared Resource facilities that advance research by providing essential technical support and instrumentation. Wistar's strength in cancer research and vaccine development, combined with the ability to move advances from the laboratory to the clinic as quickly as possible, have led to vaccines against rubella, rabies and rotavirus. Wistar's current research on targeted therapies in melanoma, tumor immunology and translational research are leading to significant developments in cancer medicine. Committed to improving health, eradicating disease, and expanding the boundaries of knowledge through research and training, the Institute works actively to ensure research advances are aimed at curing disease and improving public health. The Wistar Institute Cancer Center has a history of significant advances in cancer genetics, cancer biology, tumor immunology, and virology, and merges basic cancer research with translational advances toward cancer prevention, diagnosis, and therapy. Cancer Center scientists conduct research on gene expression and regulation, 0 0 0 46505000 1 1 0 1 0 0 0 1 0 1 1 1 0 1 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 106 0 1 382 1 1 1 0 0 0 0 1 1 0 0 0 0 X 33 33 1 0 0 0 0 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MO MS NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV X Joseph G Trainor CFO 2154956922 3601 Spruce Street Philadelphia PA 191044265 Elizabeth McKee Anderson Trustee 1.00 0 X 0 0 0 Van Billet Trustee 0.25 0 X 0 0 0 Robert S Blank Trustee 0.5 0 X 0 0 0 Douglas S Briggs Trustee 1 0 X 0 0 0 Ira Brind Trustee 1.00 0 X 0 0 0 Ronald Caplan Trustee 2.00 0 X 0 0 0 Brian H Dovey Trustee 2.00 0 X 0 0 0 Daniel K Fitzpatrick Trustee 0.25 0 X 0 0 0 Robert A Fox Trustee 2 0 X 0 0 0 George W Gephart Trustee 1.00 0 X 0 0 0 L Patrick Gage Trustee 2.00 0 X 0 0 0 Joseph A Goldblum Trustee 2 0 X 0 0 0 Richard M Horowitz Trustee 4.00 0 X 0 0 0 Herbert Kean Trustee 0.25 0 X 0 0 0 Perry Lerner Trustee 1 X 0 0 0 Maida Milone Trustee 2.00 0 X 0 0 0 Susan S McDonald Trustee 2.00 0 X 0 0 0 Abraham L Morris Trustee 1.00 0 X 0 0 0 Albert Ominsky Trustee 0.25 0 X 0 0 0 Arthur M Pappas Trustee 1.00 0 X 0 0 0 Vincent Price Trustee 0.25 0 X 0 0 0 Helen P Pudlin Trustee 5.00 0 X 0 0 0 Samuel V Rhoads Trustee 1 0 X 0 0 0 Robert H Rock Trustee 1 0 X 0 0 0 Gerald B Rorer Trustee 0.5 0 X 0 0 0 Adele K Schaeffer Trustee 1 0 X 0 0 0 Paul J Schmitt Trustee 1 0 X 0 0 0 Milton S Schneider Trustee 1 0 X 0 0 0 William A Slaughter Esq Trustee 1 0 X 0 0 0 Judith S Soltz Trustee 1 0 X 0 0 0 David V Wachs Trustee 0.25 0 X 0 0 0 Daniel H Wheeler Esq Trustee 1 0 X 0 0 0 Edward Ziff PhD Trustee 0.50 X 0 0 0 Mark L Greenberg PhD (Term expired in February 2015) 1 0 X 0 0 0 Dario Altieri MD President & CEO 55 0 X 396370 0 36989 Russel Kaufman MD President and CEO until March, 2015 55 0 X 691160 0 48535 Elizabeth OBrien Esquire VP for Legal and External Affairs 55 0 X 272668 0 55159 Anita Pepper PhD Vice President, Institutional Advancement 55 0 X 15968 0 2065 Heather A Steinman PhD VP for Business Develop & E. D. Tech 55 0 X 178847 0 30011 Alan Stiles Chief Operating Officer 55 0 X 271291 0 55100 Joseph Trainor CPA Chief Financial Officer 55 0 X 226859 0 52732 Dmitry I Gabrilovich MD PhD Professor 55 0 X 265695 0 25978 Hildegund C J Ertl MD Professor 55 0 X 229920 0 41370 Meenhard Herlyn DVM DSc Professor 55 0 X 234832 0 55395 Frank Rauscher PhD Professor 55 0 X 255328 0 32245 David W Speicher PhD Professor 55 X 229545 0 46068 3268483 0 481647 48 0 1 0 L F Driscoll Company 9 Presidential Blvd P O Box 468 Bala Cynwyd PA 19004 Construction Management 445592 The Arthur Jackson Company 1500 Market St Philadelphia PA 19102 Janitorial Services 563471 Allied Barton Security Services 161 Washington Street Suite 600 Conshohocken PA 19428 Security Services 419351 Cambridge Computer Services Inc 2021 Arch St Philadelphia PA 19103 Computer Services 248363 Ballinger 833 Chestnut Street Suite 1400 Philadelphia PA 19107 Architect & Engineer 237823 18 0 0 569000 0 29830000 15585000 539471 45984000 Research Contract Revenue 541700 3295000 3295000 0 0 0 0 0 0 3295000 2830000 0 0 2830000 0 0 0 0 41604000 0 0 41604000 55000 0 108000 0 -53000 0 -53000 0 0 -53000 41596576 75000 43253576 0 -1657000 75000 -1582000 0 0 -1582000 110000 569000 156000 -46000 0 -46000 0 0 0 0 0 0 0 0 0 0 0 0 Sale of Specialized Services 541700 108000 0 108000 0 PECO refund 900099 42000 0 0 42000 PA sales & use tax refunds 900099 29000 0 0 29000 26000 0 0 26000 205000 92237000 3295000 108000 42850000 2334000 390000 1926000 18000 0 0 0 0 17753000 12495000 5161000 97000 1895000 1334000 551000 10000 3012000 2120000 876000 16000 1239000 872000 360000 7000 0 0 0 0 371000 371000 87000 87000 67000 67000 0 0 366000 366000 1651000 231000 1052000 368000 73000 16000 57000 0 313000 18000 292000 3000 277000 138000 127000 12000 0 0 0 0 3774000 3550000 201000 23000 376000 261000 113000 2000 0 0 0 0 0 0 0 0 1683000 1579000 92000 12000 0 0 0 0 6858000 6436000 372000 50000 246000 246000 Subawards 8961000 8961000 0 0 Lab supplies and equipment agreements 7512000 6858000 644000 10000 Allocation of O & M exp 0 1246000 -1246000 308000 0 308000 0 59156000 46505000 12023000 628000 1454000 18983000 2001000 21000000 10217000 11074000 16132000 9490000 0 0 0 0 0 0 35000 90000 872000 864000 168062000 56077000 116066000 111985000 60425000 60366000 16911000 17200000 0 0 0 0 17364000 16390000 241477000 267442000 10683000 12385000 0 0 1397000 1866000 54428000 53036000 0 0 6251000 81000 0 0 7993000 6367000 80752000 73735000 X 120996000 150167000 9998000 14306000 29731000 29234000 160725000 193707000 241477000 267442000 X 33081000 -904000 0 0 0 805000 X 0 1 X 1 1 1 X 68019000 47565000 39506000 39654000 45984000 240728000 68019000 47565000 39506000 39654000 45984000 240728000 240728000 20332000 16849000 18284000 20105000 44489000 120059000 0 0 0 0 0 0 20000 0 5000 23000 97000 145000 360932000 0.66696 0.73042 X Schedule A, Part II, Line 8 $41,604,000 royalties, $2,465,000 interest/dividend, and $55,000 rent. Schedule A, Part II, Line 10 $97,000 miscellaneous income (including vendor refunds/rebates, sales and use tax refunds) RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 0 0 0 1 67000 0 0 67000 0 Schedule C, Part II-B, Line 1 The Wistar Institute engaged the services of several lobbying firms whose responsibilities are to provide government relations services to The Wistar Institute at the federal and state level with regard to both regulatory and legislative issues. Duties include monitoring and tracking legislation which may be of interest to the Wistar Institute and assisting in finding funding sources for programs. In addition, a number of Wistar staff participate in government affairs advocacy on a fairly regular basis (e.g. visits to Congressional offices to advocate for increases in the NIH budget). We also occasionally ask our board, employees or friends/volunteers to write letters or call their representatives regarding legislation that may impact Wistar. 0 0 X X X 0 18352000 129000 19000 0 848000 0 17652000 17076000 1585000 347000 0 656000 0 18352000 13462000 1537000 2563000 0 486000 0 17076000 12084000 247000 1555000 0 424000 0 13462000 12652000 50000 -214000 0 404000 0 12084000 0.13 0.72 0.15 0 0 0 685000 685000 0 90850000 27022000 63828000 0 0 0 0 0 76326000 29052000 47274000 0 201000 3000 198000 111985000 Alternative Investments 17200000 F 17200000 Other Beneficial Interest in perpetual trusts 16215000 Beneficial Interest in charitable remainder trust 175000 16390000 Accrued Pension Expense 4868000 Interest Rate Swap 1499000 6367000 X 91929000 -904000 0 0 440000 -464000 92393000 0 -156000 -156000 92237000 58947000 0 0 0 156000 156000 58791000 0 365000 365000 59156000 Schedule D, Part III, Line 1 Collections consist of Family Memorabilia and other artifacts which are not used in the Institute's operations. Schedule D, Part III, Line 4 The Institute's collections constitute a history of medical science in Philadelphia and the history of vaccine development. The museum collections are tied to our deeds of trust and have significant historical value, as Wistar was established as the first independent nonprofit biomedical research Institute in the country. Schedule D, Part V, Line 4 Management determines the prudent use for the endowment funds for general purposes and to support research and training programs as specified by the various endowment programs. Schedule D, Part X, Line 2 The institute is a non-for-profit institute which has been determined by the Internal Revenue Service to be exempt from federal income taxes under Section 501(c) (3) of the Internal Revenue Code (IRC). The Institute accounts for uncertainties in income taxes in accordance with authoritative guidance, which prescribes a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold has been met. Management believes that there were no tax uncertainties that met the recognition threshold for the years ended December 31, 2014 and 2015. Schedule D, Part XI, Line 2d Investment advisory fee = ($365,000), loss on split-interest agreements = ($977,000), Change in cash surrender value of life insurance policies = $15,000, pension-net gain = $1,535,000, interest rate swap-net gain = $232,000 Schedule D, Part XI, Line 4b Fundraising expenses = ($156,000) Schedule D, Part XII, Line 2d Fundraising event expenses are offset against revenues for the IRS 990. Schedule D, Part XII, Line 4b Investment advisory fee = $365,000 (offset against revenues in statements). Central America and the Caribbean 0 0 Investments 13337000 0 0 13337000 1 0 0 0 0 0 Schedule F, Part I, Line 1 Hedge Funds Taxin Golf Tournament 192000 169000 23000 0 1000 28000 3000 1000 13000 Wistar Gala 487000 400000 87000 0 0 2000 50000 11000 47000 0 679000 569000 110000 0 1000 30000 53000 12000 60000 156000 -46000 X X X X 0 1 X X X X 0 0 0 0 0 0 0 1 0 Russel Kaufman MD President and CEO until March, 2015 541682 0 100000 0 49478 0 34450 0 14085 0 739695 0 Dario Altieri MD President & CEO 389605 0 5000 0 1765 0 34450 0 2539 0 433359 0 Elizabeth OBrien Esquire VP for Legal and External Affairs 218896 0 10000 0 43772 0 28112 0 27047 0 327827 0 Heather A Steinman PhD VP for Business Develop & E. D. Tech 178704 0 0 0 143 0 20930 0 9081 0 208858 0 Alan Stiles Chief Operating Officer 236587 0 10000 0 24704 0 30123 0 24977 0 326391 0 Joseph Trainor CPA Chief Financial Officer 196166 0 15000 0 15693 0 26100 0 26632 0 279591 0 Dmitry I Gabrilovich MD PhD Professor 259082 0 6000 0 613 0 0 0 25978 0 291673 0 Hildegund C J Ertl MD Professor 228446 0 0 0 1473 0 28203 0 13167 0 271289 0 Meenhard Herlyn DVM DSc Professor 232395 0 0 0 2437 0 29560 0 25835 0 290227 0 Frank Rauscher PhD Professor 226449 0 0 0 28878 0 27421 0 4824 0 287572 0 David W Speicher PhD Professor 227443 0 0 0 2101 0 28405 0 17663 0 275612 0 Schedule J, Part I, Line 1a Schedule J, Part 1, Line 1a - Tax Indemnification and gross-up payments - for tuition benefits. discretionary spending account - travel and auto allowance for CEO only. Housing allowance for CEO only. Social club dues for CEO only. All amounts included in taxable compensation. Schedule J, Part I, Line 1b Schedule J, Part 1, Line 1b - Tax Indemnification and gross-up payments - yes written policy provided: Discretionary spending account, housing allowance, and social club dues are provided via employment contract with CEO. Schedule J, Part I, Line 7 Schedule J, Part 1, Line 7 - Non-fixed payments, in the form of bonuses (revenue is not a basis for a bonus), are approved by the board compensation committee. The bonuses are based on performance (including leadership). A Philadelphia Authority for Industrial Development 232237287 2011-07-29 55000000 Capital project financing 0 0 0 A 1965000 0 55000000 0 919000 0 519000 0 0 53562000 0 0 2014 0 0 1 1 A 0 0 1 1 0 0 0 0 0 0 1 A 0 0 1 0 1 1 Citizens Bank of Pennsylvania 10 0 0 0 0 1 A 1 X 26 539471 NYSE 0 0 1 1 Schedule M, Part I, Line 9 The number reported in column (b) line 9 is the number of contributions. Schedule M, Part I, Line 32b Brokerage services are used to facilitate the process of selling non-cash (stock) contributions. Form 990, Part III, Line 4a molecular and cellular oncogenesis, tumor microenvironment and metastasis, and translational tumor immunology. Its accomplishments include the identification of genes associated with breast, lung, and prostate cancer, the development of monoclonal antibodies used to study the pathways and proteins involved in tumor formation, and significant contributions to improved cancer treatments and diagnostic tests. The Wistar Institute Vaccine Center is focused on immunology, virology, vaccine development, and other research disciplines to improve public health through the creation of new and improved vaccines, in the U. S. and around the globe. The Wistar Institute has a proven record of success in vaccine development, having created the standard-of-care protections against rubella, rabies, and rotavirus. Our laboratories are dedicated to accelerating DNA-based vaccine technology, and is collaborating with established national and international academic, industry, and government partners to explore infectious diseases like Zika virus, Influenza, HIV, MERS, Ebola, CHIKV, and new emerging diseases, as well as combination therapies for ovarian, prostate, and other cancers. Lastly, dedication to education and training has always been central to The Wistar Institute's mission. In the past decade alone, nearly 1,000 promising researchers, including predoctoral students, postdoctoral fellows, and visiting scientists were trained at Wistar. This mission includes encouraging young people to consider careers in science. The Institute has also made providing science and cancer education to high school students and underserved populations in the community a priority. Wistar often hosts scientific conferences and symposia including preeminent scientists presenting original new research as well as community events and public health forums aimed at educating the public on the latest in cancer science and prevention and to stimulating learning and discussion. On July 13, 2016, the National Institutes of Health (NIH) announced the Martin Delaney Collaboratories for HIV Cure Research grant award of nearly $23 million to the BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Delaney), a consortium of top HIV researchers led by co-principal investigators at The Wistar Institute. The Philadelphia-based BEAT-HIV Delaney project is one of six grants awarded by the Delaney initiative, joining a highly-selective group of U.S.-led teams charged with advancing the global efforts to develop a cure for HIV. Form 990, Part VI, Section A, Line 2 Daniel Wheeler (Trustee) and Robert Fox (Trustee) have a family relationship. Robert Fox (Trustee) and Richard Horowitz (Trustee) have a business relationship. Form 990, Part VI, Section A, Line 7a The Academy of Natural Sciences at Drexel University and the Wistar Family have the right to designate representation to the Board of Trustees. The University of Pennsylvania approves appointments to the Board of Trustees under the Institute's founding deeds of trust. Form 990, Part VI, Section B, Line 11b The Audit Committee of the Board of Trustees reviews the 990 prior to filing the return. Also, prior to submission, the Institute posts a copy to the Board's website and notifies members of its availability for their information. Form 990, Part VI, Section B, Line 12c Annually covered persons are required to submit Conflict of Interest Disclosures which are reviewed by management. Covered persons include the Wistar Institute's trustees, officers, "key employees," and the next 5 highly compensated employees. If an individual has any power or influence to approve or disapprove a contract or transaction proposed to be entered into between the institute and any entity or person having a significant relationship o that individual, that individual has a potential conflict of interest and may not participate in the process leading to the approval or disapproval of the contract or transaction unless underlying facts giving rise to the potential conflict of interest are disclosed and approval for participation is obtained. In the case of the Board of Trustees, no individual with a potential conflict of interest with respect to a contract or transaction or any other conflict of interest may vote to approve or disapprove the contract or transaction. Form 990, Part VI, Section B, Line 15 The Board of Trustees has delegated authority to oversee the compensation paid to the organization's executives to the Executive Evaluation and Compensation Committee made up exclusively of independent members of the board of Trustees. The Committee follows the procedures set forth in the IRS regulations under Section 4958 in making compensation decisions. In particular, the committee annually conducts a review of executive compensation based on Independent compensation survey Information. At least every other year, the committee engages an Independent consultant to collect comparative compensation data and provide a written opinion on the reasonableness of the proposed compensation for executive. In 2015, the committee based its review and approval of proposed compensation on Independent data and a reasonableness opinion provided by an Independent compensation expert during the previous year, and as well as employee performance assessments and market trend information. The committee documented its compensation decision in contemporaneous written minutes. Form 990, Part VI, Section C, Line 19 The Institute's governing documents and conflict of interest policy are available on the institute's website (www.wistar.org). The Institute's financial statements are available upon request. Form 990, Part XI, Line 9 Loss on split-interest = ($977,000), Change in cash surrender value of life insurance = $15,000, Pension net loss = $1,535,000, Interest rate swap net gain = $232,000. Issac J Wistar Foundation 3601 Spruce Street Philadelphia PA 19104 232593436 Inactive PA 501 (c) (3) PF N/A 0 Tall Cell Technology L P c/o The Connelly Fdn One Tower Bridge Suite 1450 West Conshohocken PA 19428 232811246 Licensing PA The Wistar Institute of Anatomy and Biology Related 190000 1000 0 7 1 0.9 Beneficial interest in charitable remainder trust PNC Wealth Management 620 Liberty Avenue Pittsburgh PA 15222 Trust PA N/A T 0 175000 1 0 Beneficial interest in perpetual trusts BNY Mellon Wealth Management 1735 Market Street Philadelphia PA 19103 Trusts PA N/A T 875000 14490000 1 0 Beneficial interest in perpetual trusts PNC Institutional Investments 620 Liberty Avenue Pittsburgh PA 15222 Trusts PA N/A T 124000 1725000 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Tall Cell Technology L P a-iii 150000 Cost Schedule R, Part V, Line 1a The perpetual trust change in value was $998,233.